Novo Nordisk Skeptic Finally Upgrades Stock
Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK890.00.
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
3d
Investor's Business Daily on MSNNovo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results